TABLE 4.

Point dose estimates required to achieve different pharmacodynamic endpoints against MRSA 33591 at different pretreatment titers in the mouse neutropenic thigh model

Pretreatment titer and drugDose (mg/kg) for achieving pharmacodynamic endpointa
ED50EDstasisED1-log killED2-log killED3-log kill
4.9 log10 CFU/g (control)
    Telavancin1.21.84.7
    Vancomycin10.128.8100
7.1 log10 CFU/g (high)
    Telavancin7.13.59.122.480
    Vancomycin61.242.687.1288.4
  • a Doses administered i.v. —, endpoint not achieved at the doses tested.